camptothecin has been researched along with genz-644282 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bagley, RG; Bormann, C; Crawford, J; Dunham, S; Krumbholz, R; Kurtzberg, LS; Lavoie, EJ; Roth, S; Rouleau, C; Schmid, SM; Teicher, BA; Wang, F; Yao, M; Yu, XJ | 1 |
| Dexheimer, TS; Pommier, Y; Sooryakumar, D; Teicher, BA | 1 |
| Adachi, S; Anai, H; Hanada, K; Ishizaki, T; Kawano, M; Matsuoka, S; Nishida, M; Nishida, Y; Okuma, T; Tanaka, K; Terabayashi, T; Tomo, T; Tsumura, H | 1 |
3 other study(ies) available for camptothecin and genz-644282
| Article | Year |
|---|---|
Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Proliferation; Cells, Cultured; HCT116 Cells; HeLa Cells; HT29 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Models, Biological; Naphthyridines; Neoplasms; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2011 |
Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.
Topics: Antineoplastic Agents; Base Sequence; Camptothecin; Cell Line, Tumor; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; HCT116 Cells; Histones; Humans; Naphthyridines; Neoplasms; Topoisomerase I Inhibitors | 2011 |
Mechanism of action of non-camptothecin inhibitor Genz-644282 in topoisomerase I inhibition.
Topics: Aphidicolin; Arginine; Asparagine; Camptothecin; DNA; DNA Topoisomerases, Type I; Naphthyridines; Tyrosine | 2022 |